Search

Compugen Ltd

Atidarymo kaina

2.24 -5.08

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

2.27

Max

2.38

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-65M

-7.7M

Pardavimai

-65M

2.2M

P/E

Sektoriaus vid.

6.158

62.58

Pelnas, tenkantis vienai akcijai

-0.08

Pelno marža

-352.436

Darbuotojai

75

EBITDA

-64M

-7.7M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+119.3% upside

Dividendai

By Acuity

Kitas uždarbis

2026-08-03

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-49M

221M

Ankstesnė atidarymo kaina

7.32

Ankstesnė uždarymo kaina

2.24

Compugen Ltd Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-07-26 23:56; UTC

Cryptocurrency values rise as global equity markets approach $166 trillion amid mixed sentiment and geopolitical uncertainties.

2026-07-26 23:56; UTC

"Ethereum and Bitcoin rise amid mixed market sentiment as Japan shifts to expansionary fiscal policy and key economic data looms."

2026-07-26 23:56; UTC

"Ethereum Rises 4.2% Amidst Strong Global Equity Markets and Upcoming Key Economic Data Releases."

2026-07-26 23:56; UTC

Cryptocurrency gains amid cautious investor sentiment in global equities as markets brace for key economic data and Fed interest rate decision.

2026-07-26 23:52; UTC

Australia's RBA Trimmed Mean CPI Release on July 29, 2026, Expected to Impact Monetary Policy Amid Rising Trade Tensions and Cost-of-Living Concerns.

2026-07-26 23:52; UTC

Australia's Inflation Rate YoY Data Set for Release on July 29, 2026, with Forecasted Increase to 4.1%, Impacting Monetary Policy and Market Sentiment.

2026-07-26 23:51; UTC

Correlated Moves

EUR/CAD shows a slight increase in after-hours trading, reflecting volatility and aligning with a similar uptick in EUR/USD amid comparable macroeconomic factors.

2026-07-26 23:51; UTC

EUR/SEK shows notable weakness in after-hours trading, declining since Friday's close and reaching a session low amid unusual downward pressure.

2026-07-26 23:51; UTC

Macro News
Correlated Moves

Bitcoin prices have risen to $65,392, reflecting optimism amid speculation of reaching $180,000. Trade tensions could impact global markets, including cryptocurrencies.

2026-07-26 23:41; UTC

GBP/CAD advances slightly in after-hours trading, positioned near the lower end of its one-month range. No specific news was identified for the move.

2026-07-26 23:41; UTC

Upcoming U.S. Employment Cost Index report on July 31 to reveal key wage growth data amid rising inflation and consumer concerns over grocery prices.

2026-07-26 23:41; UTC

Employment Cost Index for Q2 2026 set to rise by 0.8%, signaling potential implications for inflation and Federal Reserve interest rate decisions.

2026-07-26 23:41; UTC

U.S. Employment Cost Index Benefits Data Set for Release on July 31, 2026, Amid Global Labor Market Dynamics and Inflation Concerns.

2026-07-26 23:41; UTC

Canada's preliminary monthly GDP report on July 31, 2026, is anticipated to reveal growth amid mixed economic signals and external risks.

2026-07-26 23:23; UTC

Upcoming PCE Price Index Release on July 30, 2026, Expected to Reflect Consumer Inflation Amid Rising Grocery Prices and Economic Pressures.

2026-07-26 23:23; UTC

U.S. PCE Price Index Expected to Rise 0.4% in June Amid Ongoing Inflation Concerns and Consumer Behavior Shifts

2026-07-26 23:23; UTC

U.S. Personal Spending MoM Data Release on July 30, 2026 Expected to Show 0.4% Growth Amid Rising Grocery Prices and Changing Consumer Habits.

2026-07-26 23:23; UTC

Core PCE Price Index MoM for June 2026 set to release on July 30, with a modest forecasted increase of 0.1%, as markets remain cautiously optimistic amid mixed equity performance and Fed policy discussions.

2026-07-26 23:23; UTC

US Personal Income MoM Data Release on July 30, 2026 Expected to Show Modest 0.3% Increase Amid Mixed Economic Signals

2026-07-26 23:23; UTC

U.S. GDP Price Index Forecasted to Rise 3.7% Amid Inflation Concerns Ahead of July Release

2026-07-26 23:23; UTC

U.S. Q2 2026 GDP Growth Rate Release Forecasts 2.3% Amid Cautious Market Sentiment and Rising Consumer Prices

2026-07-26 23:23; UTC

South Korea's July export growth expected to remain strong at 70.9% YoY amid market volatility and global uncertainties, with a report due August 1, 2026.

2026-07-26 23:13; UTC

South Africa's upcoming balance of trade data on July 31, 2026, is crucial as it follows a surprising May deficit amid rising imports and declining exports.

2026-07-26 23:13; UTC

S&P/Case-Shiller Home Price Index Expected to Show Modest 0.8% YoY Growth Amid Cooling U.S. Housing Market and High Inflation Concerns

2026-07-26 23:11; UTC

Correlated Moves
News

Ethereum is rising during Sunday’s trading session, gaining alongside Bitcoin amid strong market activity and global developments influencing investor sentiment.

2026-07-26 23:11; UTC

Correlated Moves
News

Ethereum is advancing during Sunday’s session, supported by Bitcoin's upward movement. The asset is trading well above recent averages amid strong market activity.

2026-07-26 23:02; UTC

After-market trading for SGD/CHF shows an upward trend, gaining since Friday's close. It is currently 1.09% above its 20-day moving average.

2026-07-26 23:01; UTC

GBP/CHF moved higher during after-market hours, reflecting strong momentum near the upper end of its one-month range. No specific news was identified.

2026-07-26 23:01; UTC

Correlated Moves

GBP/HKD is trading higher in after-market hours, reflecting a cumulative return that peaked at 0.30%. The pair shows unusual strength amid recent EUR/USD gains.

2026-07-26 23:01; UTC

Brazil's Unemployment Rate Release on July 30 Expected to Show Continued Improvement Amid Economic Optimism and External Challenges.

Akcijų palyginimas

Kainos pokytis

Compugen Ltd Prognozė

Kainos tikslas

By TipRanks

119.3% į viršų

12 mėnesių prognozė

Vidutinis 5 USD  119.3%

Aukščiausias 6 USD

Žemiausias 4 USD

Remiantis 3 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Compugen Ltd kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

3 ratings

3

Pirkti

0

Laikyti

0

Parduoti

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Compugen Ltd

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.
help-icon Live chat